We analyzed this claim: is it true that
three newly published cell-biology studies proved effective new treatments for cancer drug resistance, cancer spread and human infertility?
Laboratory experiments established basic biological mechanisms in cells and mice, but no study demonstrated a working medical treatment, improved patient survival or better fertility in humans.
Nature Cell Biology reports basic cell discoveries without new treatments
Three research teams revealed how human cells manage protein production, cell migration and early embryo attachment without producing tested medicines or clinical therapies.
In a nutshell
Three independent laboratory studies published in late October reveal how basic cellular processes govern early embryo attachment, cancer cell communication and drug resistance. While the findings expose potential targets for future medicine, including an enzyme deletion that extended survival in mice with lung cancer, none of the research has been tested in human patients or produced a new medical treatment.
Highlights
- Three peer-reviewed studies published in Nature Cell Biology between October 27 and October 29 revealed fundamental cellular mechanisms in cancer and reproduction.
- Deleting the METTL13 enzyme alongside drug treatment extended median survival in lung cancer mice to 96 days, compared with 57 days on the drug alone and 25 days untreated.
- Migrating cancer cells were shown to shed microscopic packages two to five micrometers wide carrying genetic mutations and cellular organelles.
- Laboratory co-cultures showed early human embryo models and maternal uterine tissue exchange mutual chemical signals during initial contact.
- None of the three studies tested therapies in human patients or established clinical treatments for disease or infertility.
Median survival in mouse lung cancer model
daysThe findingCombining METTL13 deletion with drug treatment prolonged mouse survival beyond drug treatment alone.
- The chart compares median survival across three test groups of mice with lung cancer.
- Sotorasib — A targeted cancer drug used to treat tumors driven by KRAS mutations
- METTL13 — A cellular enzyme that modifies protein assembly machinery
- The data highlights a potential way to combat drug resistance, but human trials are needed to see if blocking the enzyme is safe and effective in people.
From the Editor’s Diary
Understanding how cells behave under a microscope is the essential first step toward medicine, but explaining a disease mechanism is not the same as curing it.
Who's involved
International METTL13 research collaboration
Scientists from Stanford University, St. Jude Children's Research Hospital, MD Anderson Cancer Center, Karolinska Institutet and McGill University
goal → Explain how the METTL13 enzyme drives cancer growth and test whether blocking it overcomes drug resistance
Julia V. Burnier and Thupten Tsering
Cancer researchers at the Research Institute of the McGill University Health Centre in Montreal
goal → Discover how moving cancer cells shed genetic material and clarify its role in disease spread
Yixuan Wang, Shaorong Gao and the Tongji University team
Developmental biologists at Tongji University in Shanghai
goal → Construct laboratory models of early human pregnancy to identify chemical signals between embryos and the womb
Nature Cell Biology
Peer-reviewed scientific monthly published by Springer Nature
goal → Vet and publish fundamental cell research while keeping basic findings distinct from clinical treatments
Thomas M. Rawlings
Developmental biologist at the University of Cambridge who authored an accompanying expert commentary
goal → Evaluate the embryo research and explain how reciprocal signaling guides early implantation
St. Jude Children's Research Hospital
Pediatric biomedical research center in Memphis, Tennessee
goal → Conduct single-molecule imaging and evaluate the enzyme as a candidate drug target
In short
These studies matter because they show how ordinary cellular machinery can drive cancer growth or guide early human development, exposing biological weak spots that future medicine might target.
The most probable next step is laboratory work to design and test candidate drugs that block these mechanisms in animal disease models.
Whether that work yields usable human medicine remains uncertain, because moving from basic cell biology to safe, effective clinical therapies takes years and most candidates fail safety or efficacy tests along the way.
Flagged by: Life & Health Science Barometer · 31 October 2026
How it unfolded
Laboratory models reveal early embryo dialogue with the womb
The publication cluster began on October 27, when Nature Cell Biology published a study by Tongji University researchers on how early embryo-like structures and maternal tissue exchange chemical signals. The journal published an expert commentary by Cambridge researcher Thomas Rawlings alongside it. While earlier research in 2019, 2020 and 2023 had laid the groundwork for protein synthesis and cancer genetics, the three papers published this week reflect separate research programs rather than one combined clinical trial.
Early embryo attachment relies on two-way chemical signals
Implantation in human pregnancy is difficult to observe directly. To study it, Tongji University researchers combined stem-cell-derived early embryo models, called blastoids, with three-dimensional cultures of womb lining tissue. The experiments showed that specialized contact cells on the embryo adjust through a signaling pathway called CSF3 and its receptor CSF3R, while the maternal tissue alters its own gene activity in response. The study mapped a laboratory conversation between cells, but it did not test or deliver ways to treat infertility or increase successful pregnancies.
Migrating cancer cells shed microscopic packages of genetic material
On October 28, researchers at McGill University in Montreal reported that cancer cells shed previously unknown structures as they travel. These microscopic packages, called motile vesicles or MoVes, measure two to five micrometers across and pinch off from the tail ends of moving cells. They carry genomic DNA, cancer mutations and cellular energy units called mitochondria, and they altered energy activity in nearby recipient cells. The discovery reveals a new way moving cancer cells may interact with surrounding tissue, but scientists do not yet know if these packages drive tumor spread in patients or serve as useful clinical tests.
Blocking an enzyme delays cancer drug resistance in laboratory mice
On October 29, an international team led by Stanford and St. Jude addressed why tumors stop responding to targeted medicines. The scientists found that an enzyme called METTL13 modifies the protein-assembly factor eEF1A, speeding the production of specific proteins including KRAS, which fuels tumor growth. In mice with lung cancer, deleting METTL13 while continuing treatment with the targeted drug sotorasib delayed drug resistance and extended median survival to 96 days, compared with 57 days for the drug alone and 25 days without treatment. Nature Cell Biology published a research briefing on October 30. The work highlights a potential drug target, but no human medicine targeting METTL13 exists yet.
Where things stand
As of October 31, 2026, the three peer-reviewed studies are published, but none has yielded a new medical treatment, clinical diagnostic test or fertility procedure for patients.
Turning these laboratory findings into practical medical care will require developing safe compounds that work in humans, confirming whether vesicle packages drive cancer spread in clinical patients, and testing whether embryo communication pathways improve pregnancy outcomes.